Liu W, Lang M, Youdim MB, Amit T, Sun Y, Zhang Z, Wang Y, Weinreb O (2016) <br />Design, synthesis and evaluation of novel dual monoamine-cholinesterase inhibitors as potential treatment for Alzheimer's disease<br /><i>Neuropharmacology</i> <b>109</b>: 376<br /><br />Weinreb O, Amit T, Bar-Am O, Youdim MB (2016) <br />Neuroprotective effects of multifaceted hybrid agents targeting MAO, cholinesterase, iron and beta-amyloid in ageing and Alzheimer's disease<br /><i>British Journal of Pharmacology</i> <b>173</b>: 2080<br /><br />Weinreb O, Amit T, Bar-Am O, Youdim MB (2012) <br />Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment<br /><i>Curr Drug Targets</i> <b>13</b>: 483<br /><br />Zheng H, Amit T, Bar-Am O, Fridkin M, Youdim MB, Mandel SA (2012) <br />From anti-Parkinson's drug rasagiline to novel multitarget iron chelators with acetylcholinesterase and monoamine oxidase inhibitory and neuroprotective properties for Alzheimer's disease<br /><i>J Alzheimers Dis</i> <b>30</b>: 1<br /><br />Weinreb O, Amit T, Bar-Am O, Youdim MB (2011) <br />A novel anti-Alzheimer's disease drug, ladostigil neuroprotective, multimodal brain-selective monoamine oxidase and cholinesterase inhibitor<br /><i>International Review of Neurobiology</i> <b>100</b>: 191<br /><br />Bar-Am O, Amit T, Weinreb O, Youdim MB, Mandel S (2010) <br />Propargylamine containing compounds as modulators of proteolytic cleavage of amyloid-beta protein precursor: involvement of MAPK and PKC activation<br /><i>J Alzheimers Dis</i> <b>21</b>: 361<br /><br />Bar-Am O, Weinreb O, Amit T, Youdim MB (2009) <br />The novel cholinesterase-monoamine oxidase inhibitor and antioxidant, ladostigil, confers neuroprotection in neuroblastoma cells and aged rats<br /><i>Journal of Molecular Neuroscience</i> <b>37</b>: 135<br /><br />Weinreb O, Mandel S, Bar-Am O, Yogev-Falach M, Avramovich-Tirosh Y, Amit T, Youdim MB (2009) <br />Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs<br /><i>Neurotherapeutics</i> <b>6</b>: 163<br /><br />Weinreb O, Amit T, Bar-Am O, Yogev-Falach M, Youdim MB (2008) <br />The neuroprotective mechanism of action of the multimodal drug ladostigil<br /><i>Front Biosci</i> <b>13</b>: 5131<br /><br />Weinreb O, Bar-Am O, Amit T, Drigues N, Sagi Y, Youdim MB (2008) <br />The neuroprotective effect of ladostigil against hydrogen peroxide-mediated cytotoxicity<br /><i>Chemico-Biological Interactions</i> <b>175</b>: 318<br /><br />Bar-Am O, Amit T, Youdim MB (2007) <br />Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro<br /><i>Journal of Neurochemistry</i> <b>103</b>: 500<br /><br />Yogev-Falach M, Bar-Am O, Amit T, Weinreb O, Youdim MB (2006) <br />A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing<br /><i>FASEB Journal</i> <b>20</b>: 2177<br /><br />Youdim MB, Amit T, Bar-Am O, Weinreb O, Yogev-Falach M (2006) <br />Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective-neurorescue drugs; ladostigil<br /><i>Neurotox Res</i> <b>10</b>: 181<br /><br />Youdim MB, Bar Am O, Yogev-Falach M, Weinreb O, Maruyama W, Naoi M, Amit T (2005) <br />Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition<br /><i>Journal of Neuroscience Research</i> <b>79</b>: 172<br /><br />Bar-Am O, Yogev-Falach M, Amit T, Sagi Y, Youdim MB (2004) <br />Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo<br /><i>Journal of Neurochemistry</i> <b>89</b>: 1119<br /><br />Youdim MB, Amit T, Avramovich Y, Bar-Am O, Weinstock M, Yogev-Falach M (2004) <br />PKC and MAP kinase-dependent processing of amyloid precursor protein (APP) by neuroprotective propargylamine cholinesterase inhibitors derived from rasagiline and nonsteroidal anti-inflammatory drugs.<br /><i>Cholinergic Mechanisms, CRC Press</i> <br /><br />Youdim MB, Sagi Y, Derigus N, Naoi M, Maruyama W, Amit T, Falash-Yogev M, Weinstock M (2004) <br />Poster (57) A novel neuroprotective trifunctional cholinesterase inhibitor derivative of the antiparkinson drug, rasagiline, for treatment of dementia and lewy body disease co-morbid with depression<br /><i>In: Cholinesterases in the Second Millennium: Biomolecular and Pathological Aspects</i> <b> (Inestrosa NC, Campos EO) P. Universidad Catolica de Chile-FONDAP Biomedicina</b>: 351<br /><br />Youdim MB, Amit T, Bar-Am O, Weinstock M, Yogev-Falach M (2003) <br />Amyloid Processing and Signal Transduction Properties of Antiparkinson-Antialzheimer Neuroprotective Drugs Rasagiline and TV3326<br /><i>Annals of the New York Academy of Sciences</i> <b>993</b>: 378<br /><br />Yogev-Falach M, Amit T, Bar-Am O, Weinstock M, Youdim MB (2002) <br />The involvement of mitogen-activated protein (MAP) kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline<br /><i>FASEB Journal</i> <b>16</b>: 1674<br /><br />